Report cover image

Global RNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 196 Pages
SKU # APRC20552858

Description

Summary

According to APO Research, The global RNA Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of RNA Vaccines include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for RNA Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of RNA Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for RNA Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNA Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global RNA Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for RNA Vaccines sales, projected growth trends, production technology, application and end-user industry.

RNA Vaccines Segment by Company

Translate Bio
Tiba Biotechnology
Sangamo Therapeutics
Moderna Therapeutics
In-Cell-Art
Ethris
eTheRNA
CureVac
BioNTech
Argos Therapeutics
RNA Vaccines Segment by Type

Individualized Cancer Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
RNA Vaccines Segment by Application

Infectious Disease
Cancer
Other
RNA Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the RNA Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of RNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of RNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global RNA Vaccines Market Size, 2020 VS 2024 VS 2031
1.3 Global RNA Vaccines Market Size Estimates and Forecasts (2020-2031)
1.4 Global RNA Vaccines Sales Estimates and Forecasts (2020-2031)
1.5 Global RNA Vaccines Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global RNA Vaccines Market Dynamics
2.1 RNA Vaccines Industry Trends
2.2 RNA Vaccines Industry Drivers
2.3 RNA Vaccines Industry Opportunities and Challenges
2.4 RNA Vaccines Industry Restraints
3 RNA Vaccines Market by Manufacturers
3.1 Global RNA Vaccines Revenue by Manufacturers (2020-2025)
3.2 Global RNA Vaccines Sales by Manufacturers (2020-2025)
3.3 Global RNA Vaccines Average Sales Price by Manufacturers (2020-2025)
3.4 Global RNA Vaccines Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global RNA Vaccines Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global RNA Vaccines Manufacturers, Product Type & Application
3.7 Global RNA Vaccines Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global RNA Vaccines Market CR5 and HHI
3.8.2 Global Top 5 and 10 RNA Vaccines Players Market Share by Revenue in 2024
3.8.3 2024 RNA Vaccines Tier 1, Tier 2, and Tier 3
4 RNA Vaccines Market by Type
4.1 RNA Vaccines Type Introduction
4.1.1 Individualized Cancer Treatment MRNA Vaccine
4.1.2 Infection Prevention MRNA Vaccine
4.1.3 Infectious Disease Treatment MRNA Vaccine
4.2 Global RNA Vaccines Sales by Type
4.2.1 Global RNA Vaccines Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global RNA Vaccines Sales by Type (2020-2031)
4.2.3 Global RNA Vaccines Sales Market Share by Type (2020-2031)
4.3 Global RNA Vaccines Revenue by Type
4.3.1 Global RNA Vaccines Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global RNA Vaccines Revenue by Type (2020-2031)
4.3.3 Global RNA Vaccines Revenue Market Share by Type (2020-2031)
5 RNA Vaccines Market by Application
5.1 RNA Vaccines Application Introduction
5.1.1 Infectious Disease
5.1.2 Cancer
5.1.3 Other
5.2 Global RNA Vaccines Sales by Application
5.2.1 Global RNA Vaccines Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global RNA Vaccines Sales by Application (2020-2031)
5.2.3 Global RNA Vaccines Sales Market Share by Application (2020-2031)
5.3 Global RNA Vaccines Revenue by Application
5.3.1 Global RNA Vaccines Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global RNA Vaccines Revenue by Application (2020-2031)
5.3.3 Global RNA Vaccines Revenue Market Share by Application (2020-2031)
6 Global RNA Vaccines Sales by Region
6.1 Global RNA Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global RNA Vaccines Sales by Region (2020-2031)
6.2.1 Global RNA Vaccines Sales by Region (2020-2025)
6.2.2 Global RNA Vaccines Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America RNA Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America RNA Vaccines Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe RNA Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe RNA Vaccines Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific RNA Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific RNA Vaccines Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa RNA Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa RNA Vaccines Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global RNA Vaccines Revenue by Region
7.1 Global RNA Vaccines Revenue by Region
7.1.1 Global RNA Vaccines Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global RNA Vaccines Revenue by Region (2020-2025)
7.1.3 Global RNA Vaccines Revenue by Region (2026-2031)
7.1.4 Global RNA Vaccines Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America RNA Vaccines Revenue (2020-2031)
7.2.2 North America RNA Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe RNA Vaccines Revenue (2020-2031)
7.3.2 Europe RNA Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific RNA Vaccines Revenue (2020-2031)
7.4.2 Asia-Pacific RNA Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa RNA Vaccines Revenue (2020-2031)
7.5.2 South America, Middle East and Africa RNA Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Translate Bio
8.1.1 Translate Bio Comapny Information
8.1.2 Translate Bio Business Overview
8.1.3 Translate Bio RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Translate Bio RNA Vaccines Product Portfolio
8.1.5 Translate Bio Recent Developments
8.2 Tiba Biotechnology
8.2.1 Tiba Biotechnology Comapny Information
8.2.2 Tiba Biotechnology Business Overview
8.2.3 Tiba Biotechnology RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Tiba Biotechnology RNA Vaccines Product Portfolio
8.2.5 Tiba Biotechnology Recent Developments
8.3 Sangamo Therapeutics
8.3.1 Sangamo Therapeutics Comapny Information
8.3.2 Sangamo Therapeutics Business Overview
8.3.3 Sangamo Therapeutics RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
8.3.5 Sangamo Therapeutics Recent Developments
8.4 Moderna Therapeutics
8.4.1 Moderna Therapeutics Comapny Information
8.4.2 Moderna Therapeutics Business Overview
8.4.3 Moderna Therapeutics RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Moderna Therapeutics RNA Vaccines Product Portfolio
8.4.5 Moderna Therapeutics Recent Developments
8.5 In-Cell-Art
8.5.1 In-Cell-Art Comapny Information
8.5.2 In-Cell-Art Business Overview
8.5.3 In-Cell-Art RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 In-Cell-Art RNA Vaccines Product Portfolio
8.5.5 In-Cell-Art Recent Developments
8.6 Ethris
8.6.1 Ethris Comapny Information
8.6.2 Ethris Business Overview
8.6.3 Ethris RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Ethris RNA Vaccines Product Portfolio
8.6.5 Ethris Recent Developments
8.7 eTheRNA
8.7.1 eTheRNA Comapny Information
8.7.2 eTheRNA Business Overview
8.7.3 eTheRNA RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 eTheRNA RNA Vaccines Product Portfolio
8.7.5 eTheRNA Recent Developments
8.8 CureVac
8.8.1 CureVac Comapny Information
8.8.2 CureVac Business Overview
8.8.3 CureVac RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 CureVac RNA Vaccines Product Portfolio
8.8.5 CureVac Recent Developments
8.9 BioNTech
8.9.1 BioNTech Comapny Information
8.9.2 BioNTech Business Overview
8.9.3 BioNTech RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 BioNTech RNA Vaccines Product Portfolio
8.9.5 BioNTech Recent Developments
8.10 Argos Therapeutics
8.10.1 Argos Therapeutics Comapny Information
8.10.2 Argos Therapeutics Business Overview
8.10.3 Argos Therapeutics RNA Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Argos Therapeutics RNA Vaccines Product Portfolio
8.10.5 Argos Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 RNA Vaccines Value Chain Analysis
9.1.1 RNA Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 RNA Vaccines Production Mode & Process
9.2 RNA Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 RNA Vaccines Distributors
9.2.3 RNA Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.